CARD9 and nervous system disorder: Taken together, these findings indicate that the innate immune signaling molecule CARD9 is a regulator of Aβ-mediated neurological disease and further suggest that targeting CARD9 activation may offer a therapeutic strategy to promote Aβ clearance.